...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular and Cellular Endocrinology >Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours
【24h】

Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours

机译：甲状腺髓样癌的表观遗传相关基因表达谱显示侵袭性肿瘤中组蛋白甲基转移酶EZH2和SMYD3过表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Epigenetic control of gene expression plays a major influence in the development and progression of many cancer types. Aim of the present study was to investigate the expression of epigenetic regulators in a large cohort of medullary thyroid carcinomas (MTC), correlating the data with the clinical outcome and mutational status of the patients. Taqman Low Density Arrays (TLDAs) were used to analyze expression levels of several genes involved in the epigenetic control of transcription in a series of 54 MTCs. The patients cohort included 13 familial MTCs and 41 sporadic forms; 33 hosted a RET mutation and 13 a RAS somatic mutation. The expression profiling revealed in the more aggressive diseases (i.e. occurrence of metastases; persistent disease; disease-related death) a significant increase of EZH2 and SMYD3 gene expression. The increased levels of EZH2 and SMYD3 did not correlate significantly with mutational status of RET or MS genes. Thus, the histone methyltransferases EZH2 and SMYD3 mRNA expression may represent useful prognostic biomarkers tailoring the most appropriate follow-up and timing of therapeutic approaches. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
机译：基因表达的表观遗传控制在许多癌症类型的发生和发展中起着重要的作用。本研究的目的是调查表观遗传调控因子在甲状腺髓样癌（MTC）大群中的表达，并将数据与患者的临床结果和突变状态相关联。 Taqman低密度阵列（TLDA）用于分析一系列54个MTC中参与表观遗传控制转录的几种基因的表达水平。患者队列包括13个家族MTC和41个散发形式; 33例为RET突变，而13例为RAS体细胞突变。表达谱揭示了在更具侵略性的疾病（即转移的发生;持续性疾病;与疾病相关的死亡）中，EZH2和SMYD3基因表达显着增加。 EZH2和SMYD3水平的升高与RET或MS基因的突变状态没有显着相关。因此，组蛋白甲基转移酶EZH2和SMYD3 mRNA的表达可能代表了有用的预后生物标志物，可用于调整治疗方法的最合适的随访和时机。 （C）2014 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号